Want to see IN:BAJAJHCARE full AI Analyst Report?
BAJAJHCARE Stock Chart & Stats
₹418.50
-₹31.80(-5.51%)
At close: 4:00 PM EST
₹418.50
-₹31.80(-5.51%)
Day’s Range― - ―
52-Week Range₹272.45 - ₹484.40
Previous CloseN/A
Volume215.90K
Average Volume (3M)12.02K
Market Cap
₹10.31B
Enterprise Value₹13.67B
Total Cash (Recent Filing)₹142.20M
Total Debt (Recent Filing)₹2.82B
Price to Earnings (P/E)50.5
Beta1.37
Next Earnings
Jan 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)6.06
Shares Outstanding33,665,160
10 Day Avg. Volume12,852
30 Day Avg. Volume12,019
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)1.72
Price to Sales (P/S)1.50
P/FCF Ratio-149.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product And Market BreadthOperating across APIs, intermediates and finished dosages gives Bajaj Healthcare multiple pharmaceutical product and process channels, serving domestic and export drug makers. This breadth can support customer diversification and provide more avenues for growth than a single-product model over the medium term.
Improved LeverageDebt-to-equity improved to about 0.47 in FY2026 from above 1.0 in FY2023–FY2024, supported by a larger equity base. The lower leverage and more stable capital structure improve financial flexibility and reduce balance-sheet pressure as the company funds ongoing operations and growth.
Revenue RecoveryRevenue recovered 6.4% in FY2026 after a weak FY2024 decline, indicating renewed demand and business activity. A return to growth provides a platform for scale benefits and reinvestment, although sustaining that recovery will depend on converting sales momentum into stronger net earnings.
Bears Say
Profitability VolatilityProfitability remains fragile: the company recorded a FY2024 loss, while FY2026 net margin fell to about 2.6% from 7.3% in FY2025. Such swings reduce earnings visibility and leave less internal funding for expansion, making durable returns dependent on meaningful margin stabilization.
Weak Free Cash FlowFree cash flow stayed negative at about -61M in FY2026 despite operating cash flow of roughly 372M, and several earlier years also recorded sizable negative FCF. Persistent weak cash conversion can constrain self-funded investment and increase reliance on external funding during downturns.
Uneven Revenue TrendThe revenue trajectory is uneven, with FY2026's 6.4% rebound following a weak FY2024 decline rather than a consistently expanding trend. This variability makes demand planning and operating leverage less predictable and raises the risk that growth will not translate into steady earnings over the next several quarters.
Bajaj Healthcare Ltd News
BAJAJHCARE FAQ
What was Bajaj Healthcare Ltd’s price range in the past 12 months?
Bajaj Healthcare Ltd lowest stock price was ₹272.45 and its highest was ₹484.40 in the past 12 months.
What is Bajaj Healthcare Ltd’s market cap?
Bajaj Healthcare Ltd’s market cap is ₹10.31B.
When is Bajaj Healthcare Ltd’s upcoming earnings report date?
Bajaj Healthcare Ltd’s upcoming earnings report date is Jan 22, 2027 which is in 83 days.
How were Bajaj Healthcare Ltd’s earnings last quarter?
Bajaj Healthcare Ltd released its earnings results on Oct 17, 2026. The company reported ₹4.186 earnings per share for the quarter.
Is Bajaj Healthcare Ltd overvalued?
According to Wall Street analysts Bajaj Healthcare Ltd’s price is currently Overvalued.
Does Bajaj Healthcare Ltd pay dividends?
Bajaj Healthcare Ltd pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.49%. See more information on Bajaj Healthcare Ltd dividends here
What is Bajaj Healthcare Ltd’s EPS estimate?
Bajaj Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bajaj Healthcare Ltd have?
Bajaj Healthcare Ltd has 33,665,160 shares outstanding.
What happened to Bajaj Healthcare Ltd’s price movement after its last earnings report?
Bajaj Healthcare Ltd reported an EPS of ₹4.186 in its last earnings report. Following the earnings report the stock price went up 2.901%.
Which hedge fund is a major shareholder of Bajaj Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:BAJAJHCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bajaj Healthcare Ltd
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 amino 1 adamantanol, N boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Technical Analysis
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Themis Medicare Limited
―
Wanbury Limited
―






